Serum metabolome analysis by 1H-NMR reveals differences between chronic lymphocytic leukaemia
CRUK (Cancer Research UK) 2014: Chronic lymphocytic leukaemia
(CLL) incidence statistics.
Chronic lymphocytic leukaemia
is a form of blood cancer and the most common in adults in the western world, with 3100 people diagnosed with it in the UK every year.
The Phase III trial (OMB110911, COMPLEMENT 1) assessed the combination of ofatumumab and chlorambucil versus chlorambucil alone in chronic lymphocytic leukaemia
patients, while the Phase II trial (OMB115991) evaluated ofatumumab in combination with bendamustine in 44 patients with earlier untreated chronic lymphocytic leukaemia
For example, we have discovered that large amounts of a molecule called NF-kB is linked to the growth of chronic lymphocytic leukaemia
A bone marrow biopsy confirmed marrow infiltration by B-cell chronic lymphocytic leukaemia
We hope to use this new knowledge to directly help patients with chronic lymphocytic leukaemia
to live as long and as normal a life as possible.
William Plunkett referred to the ongoing investigator-sponsored Phase I clinical study of clofarabine in chronic lymphocytic leukaemia
com)-- The new Chronic Lymphocytic Leukaemia
(CLL) Knowledge Centre is live on online medical education site epgonline.
The data from the trial indicated that among the patients with chronic lymphocytic leukaemia
who received at least eight weeks of GS-9973 monotherapy, 97% of them experienced a decrease in lymph node size.
Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJ, Bezares RF, Pettitt AR, Hamblin T, Milligan DW, Child JA, Hamilton MS, Dearden CE, Smith AG, Bosanquet AG, Davis Z, Brito-Babapulle V, Else M, Wade R, Hillmen P; UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group; NCRI Chronic Lymphocytic Leukaemia
Researchers have been awarded a grant to investigate a protein involved in chronic lymphocytic leukaemia
It was reported yesterday that the combination therapy would be utilised to treat chronic lymphocytic leukaemia
patients who have not received prior treatment and are inappropriate for fludarabine-based therapy.
14 December 2011 - Pharmacyclics Inc (NASDAQ:PCYC), a US-based biopharmaceutical company developing new treatments for cancer and immune mediated diseases, unveiled on Tuesday updated results of a Phase Ib/II trial of the selective, irreversible Bruton's tyrosine kinase (BTK) inhibitor, PCI-32765, in patients with relapsed or refractory chronic lymphocytic leukaemia
(CLL)/small lymphocytic lymphoma (SLL).